Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.

Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Aug 2026

Gariazzo Eleonora, Elkrief Arielle, Concannon Kyle, Ognissanti Daniele, Dodi Alessandra, Favorito Valentina, Di Federico Alessandro, De Giglio Andrea, Brunetti Leonardo, Santo Valentina, Pecci Federica, Aldea Mihaela, Garbo Edoardo, Alessi Joao V, LoPiccolo Jaclyn, Paoloni Francesco, Nishino Mizuki, Sholl Lynette M, Florez Narjust, Rotow Julia, Frumm Stacey M, Hong Lingzhi, Zhang Jianjun, Gibbons Don, Wang Xinan, Landi Lorenza, Cipriani Laura, Rakaee Mehrdad, Cortellini Alessio, Tiseo Marcello, Cappuzzo Federico, Ardizzoni Andrea, Awad Mark M, Heymach John V, Scalera Stefano, Maugeri-Saccà Marcello, Metro Giulio, Vokes Natalie, Schoenfeld Adam, Ricciuti Biagio

Abstract excerpt

PURPOSE: Predictive biomarkers of response to immune checkpoint inhibitors (ICI) remain poorly defined in patients with non-small cell lung cancer (NSCLC) without a history of tobacco use and lacking actionable genomic alterations (AGA). We aimed to identify clinical and molecular predictors of response to ICI-based regimens in patients who have never smoked and lack AGAs. EXPERIMENTAL DESIGN: We retrospectively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to B7-H1 Antigen
Share to Biomarkers, Tumor
Share to Carcinoma, Non-Small-Cell Lung
Share to Immune Checkpoint Inhibitors
Share to Lung Neoplasms
Share to Lymphocytes, Tumor-Infiltrating
Share to Prognosis
Share to Treatment Outcome

Source

Identifiers

PMID: 42149140
DOI: 10.1158/1078-0432.CCR-25-4793

Genes

AGA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Outcomes and Predictors of Response to PD-(L)1 Blockade in Patients with NSCLC without Actionable Genomic Alterations Who Never Used Tobacco.PMID 42149140Read ↗

Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.Semantic proximity Read ↗

Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.Semantic proximity Read ↗

Biomarkers of success of anti-PD-(L)1 immunotherapy for non-small cell lung cancer derived from RNA- and whole-exome sequencing: results of a prospective observational study on a cohort of 85 patients.Semantic proximity Read ↗

Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung CancerSemantic proximity Read ↗

Comprehensive molecular profiling of squamous non-small cell lung cancer reveals high incidence of actionable genomic alterations among patients with no history of smoking.Semantic proximity Read ↗

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Semantic proximity Read ↗

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.Semantic proximity Read ↗

From Exposure to Biomarker: Cumulative Tobacco Burden and Integrated Multiomics Signatures of High Tumor Mutational Burden in Lung Adenocarcinoma-A Secondary Analysis of the Cancer Genome Atlas.Semantic proximity Read ↗

TTF-1 Expression in Lung Adenocarcinoma: Clinicopathologic, Genomic, and Immunophenotypic Correlates and Outcomes to Immunotherapy-Based Treatments and KRASG12C Inhibitors.Semantic proximity Read ↗

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.